Form 4: Karyopharm Therapeutics EVP, CFO & Treasurer Michael Mason Sells Shares to Cover Tax Obligations

Michael Mason, EVP, CFO & Treasurer of Karyopharm Therapeutics, sold shares of common stock on February 29, 2024, and March 1, 2024, to cover withholding tax liabilities.

Summary

• Michael Mason, the EVP, CFO & Treasurer of Karyopharm Therapeutics Inc., reported the sale of company stock.
• On February 29, 2024, he sold 27,687 shares of common stock at a price of $1.17 per share.
• On March 1, 2024, he sold 6,162 shares of common stock at a price of $1.20 per share.
• These sales were executed under a pre-arranged automatic sale instruction plan adopted on June 10, 2021, to cover withholding tax obligations related to the vesting of restricted stock units and performance-based restricted stock units.
• Following these transactions, Mason directly owns 398,756 shares of Karyopharm Therapeutics Inc.
• The weighted average sale price on February 29, 2024, was $1.17, with individual sales ranging from $1.12 to $1.18.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the sales are related to tax obligations and executed under a pre-arranged plan, not necessarily reflecting a negative view of the company's prospects.

Positives

• The sales were executed under a pre-arranged plan, indicating they were not based on current market sentiment or inside information.

Industry Context

Insider sales are a common occurrence, especially when related to tax obligations from vesting equity. Investors often monitor these transactions to gauge management's sentiment and confidence in the company's future prospects. However, sales under pre-arranged plans are generally viewed as less informative than discretionary trades.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholders due to the increased supply of shares in the market, but the impact is likely to be minimal given the relatively small volume of shares sold.

Key Dates